Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease
- PMID: 39128198
- DOI: 10.1016/j.vaccine.2024.126177
Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease
Abstract
High-risk human papillomavirus (HPV) infections can progress to cervical cancer which is the fourth most common cancer in women globally. In Scotland, the incidence of cervical cancer has a strong socioeconomic deprivation gradient disproportionately affecting women from more deprived areas. An HPV vaccination programme was initiated in Scotland in 2008 targeting girls aged 12-13 years with a catch-up campaign running for the first three years for girls aged up to 18 years. The programme has evolved over the last 16 years with changes in the type of vaccine, dosing schedules and the extension of the programme to boys and gay, bisexual and other men who have sex with men. Vaccine uptake in Scotland has historically been high but has gradually decreased over time and disparities exist in women from more deprived areas of Scotland. The ability to link national immunisation and screening databases in Scotland has allowed direct monitoring of the impact of the HPV vaccine on virological and histological outcomes. Analyses of this linked data have demonstrated real-world evidence of high vaccine effectiveness against HPV infection, cervical disease, and cervical cancer with evidence of herd immunity in unvaccinated women. Continued monitoring is crucial to assess the duration of protection, the impact of vaccine and dosing schedules changes and the emergence of potential type replacement. With the World Health Organisation's aim to eliminate cervical cancer as a public health problem by the next century addressing the inequalities in cervical cancer incidence will be crucial. This will require targeted interventions for women most at risk of cervical cancer to ensure elimination is achieved timely for all women in Scotland.
Keywords: Papillomavirus infections; Papillomavirus vaccines; Public health surveillance; Scotland; Uterine cervical neoplasms.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kate Cuschieri reports a relationship with Hologic Inc. that includes: funding grants and travel reimbursement. Kate Cuschieri reports a relationship with Barinthus Biotherapeutics plc that includes: funding grants and non-financial support. Kate Cuschieri reports a relationship with EUROIMMUN Medizinische Labordiagnostika AG that includes: funding grants. Kate Cuschieri reports a relationship with GeneFirst that includes: funding grants. Kate Cuschieri reports a relationship with Hiantis that includes: funding grants. Kate Cuschieri reports a relationship with Seegene, Inc. that includes: funding grants. Kate Cuschieri reports a relationship with Roche that includes: funding grants. Kate Cuschieri reports a relationship with Daye that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.J Epidemiol Community Health. 2017 Oct;71(10):954-960. doi: 10.1136/jech-2017-209113. Epub 2017 Jul 29. J Epidemiol Community Health. 2017. PMID: 28756395
-
Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.BMJ. 2024 May 15;385:e077341. doi: 10.1136/bmj-2023-077341. BMJ. 2024. PMID: 38749552 Free PMC article.
-
Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.BMJ. 2019 Apr 3;365:l1161. doi: 10.1136/bmj.l1161. BMJ. 2019. PMID: 30944092 Free PMC article.
-
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?Euro Surveill. 2018 Oct;23(41):1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737. Euro Surveill. 2018. PMID: 30326995 Free PMC article. Review.
-
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.J Manag Care Pharm. 2010 Apr;16(3):217-30. doi: 10.18553/jmcp.2010.16.3.217. J Manag Care Pharm. 2010. PMID: 20331326 Free PMC article. Review.
Cited by
-
Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States.J Natl Cancer Inst. 2025 May 1;117(5):924-933. doi: 10.1093/jnci/djae327. J Natl Cancer Inst. 2025. PMID: 39658224 Free PMC article.
-
Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review.Hum Vaccin Immunother. 2025 Dec;21(1):2497608. doi: 10.1080/21645515.2025.2497608. Epub 2025 Jun 9. Hum Vaccin Immunother. 2025. PMID: 40485552 Free PMC article. Review.
-
The relationship between human papillomavirus (HPV) knowledge and HPV vaccine acceptance among women and affecting factors in Türkiye.Cancer Causes Control. 2025 Jun 22. doi: 10.1007/s10552-025-02023-1. Online ahead of print. Cancer Causes Control. 2025. PMID: 40545508
-
HPV vaccine impact: genotype-specific changes in cervical pre-cancer share similarities with changes in cervical screening cytology.J Natl Cancer Inst. 2025 Jul 1;117(7):1377-1386. doi: 10.1093/jnci/djaf055. J Natl Cancer Inst. 2025. PMID: 40069924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical